• Subscribe
  • Advertise
  • About us
  • Follow
  • Follow
  • Follow
  • Follow
Pharmafile Logo
  • Magazine
    • PharmaTimes Magazine Archive
  • Web Exclusives
  • News
  • Competitions
  • Appointments
  • Business Insights
  • Webinars
  • Thought Leadership

Mylan pays $17.5 million for Pfizer’s copy of Advair

by PharmaTimes | 1st Jan 2000 | News

Tags


Related posts

Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay

Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay

Feb 3, 2026

IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease

IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease

Feb 3, 2026

En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation

En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation

Feb 2, 2026

ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children

Feb 2, 2026

News alerts

This field is required.

Latest content

  • Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
  • IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
  • En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
  • ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
  • CERo reports encouraging early data from phase 1 trial of CER‑1236

Contact details

PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN

E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999

Get the latest pharma news delivered to your inbox

A valid email address is required.

Download our apps

Go to the App Store or Google Play and search for ‘PharmaTimes’ to download our free app.

Content

News
Magazine
Advertise
Contact
Competitions

Connect

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Legal

Privacy Policy
Terms and Conditions
Editorial policy
Cookies
RSS – feed subscriptions
© Copyright PharmaTimes Media Limited 2026